Mobile

A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH...

Update Il y a 4 ans
Reference: EUCTR2014-000576-26

A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON-HODGKIN’S LYMPHOMA

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the efficacy of GDC-0199 plus Bendamustine and Rituximab (BR) compared with BR alone in patients with R/R FL. To evaluate the efficacy of GDC-0199 plus rituximab in patients with Relapsed and Refractory Follicular non-hodgkins Lymphoma (R/R FL)

Inclusion criteria

  • Relapsed and refractory follicular non-Hodgkins Lymphoma (R/R FL)

Links